Halozyme (NASDAQ: HALO) CEO exercises 40k options, sells 40k shares

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported an exercise-and-sell transaction in company stock. On April 1–2, she exercised options to acquire a total of 40,000 shares of common stock at an exercise price of $12.0700 per share, from options with a ten-year term expiring in February 2027.

Over the same two days, she sold 40,000 shares of common stock in open-market trades at per-share prices including $65.3580, $65.7140, $64.0630 and $64.8870. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly owned 767,780 shares of Halozyme common stock.

Insider Trade Summary 10b5-1

Net Seller: 40,000 shares ($2,592,237)

Net Sell 8 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Sold 40,000 shs ($2.59M)

Type	Security	Shares	Price	Value
Exercise	Option to Purchase Common Stock	20,000	$12.07	$241K
Exercise	Common Stock	20,000	$12.07	$241K
Sale	Common Stock	15,800	$64.063	$1.01M
Sale	Common Stock	4,200	$64.887	$273K
Exercise	Option to Purchase Common Stock	20,000	$12.07	$241K
Exercise	Common Stock	20,000	$12.07	$241K
Sale	Common Stock	19,000	$65.358	$1.24M
Sale	Common Stock	1,000	$65.714	$66K

Holdings After Transaction: Option to Purchase Common Stock — 111,923 shares (Direct); Common Stock — 787,780 shares (Direct)

Footnotes (1)

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.650 to $65.640. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.660 to $65.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.650 to $64.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.660 to $65.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

Key Figures

Options exercised: 40,000 shares Shares sold: 40,000 shares Option exercise price: $12.0700 per share +3 more

6 metrics

Options exercised 40,000 shares Total underlying shares from option exercises on April 1–2, 2026

Shares sold 40,000 shares Aggregate common shares sold in open-market trades on April 1–2, 2026

Option exercise price $12.0700 per share Exercise price for options to purchase Halozyme common stock

Post-transaction holdings 767,780 shares Common shares directly owned by Helen Torley after final sale

Sale tranche 19,000 shares at $65.3580 One reported open-market sale of Halozyme common stock on April 1, 2026

Option term 10 years, expiring February 2027 Ten-year stock option term ending in February 2027 per footnote

Key Terms

Rule 10b5-1, weighted average sales price per share, stock options, ten-year term, +1 more

5 terms

Rule 10b5-1 regulatory

"written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sales price per share financial

"Represents a weighted average sales price per share. The shares were sold at prices ranging from"

stock options financial

"shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

ten-year term financial

"exercise of stock options with a ten-year term expiring in February 2027"

Form 4 regulatory

"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M(1)		20,000	A	$12.07	787,780	D
Common Stock	04/01/2026		S(1)		19,000	D	$65.358(2)	768,780	D
Common Stock	04/01/2026		S(1)		1,000	D	$65.714(3)	767,780	D
Common Stock	04/02/2026		M(1)		20,000	A	$12.07	787,780	D
Common Stock	04/02/2026		S(1)		15,800	D	$64.063(4)	771,980	D
Common Stock	04/02/2026		S(1)		4,200	D	$64.887(5)	767,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$12.07	04/01/2026		M(1)			20,000	(6)	02/22/2027	Common Stock	20,000	$12.07	131,923	D
Option to Purchase Common Stock	$12.07	04/02/2026		M(1)			20,000	(6)	02/22/2027	Common Stock	20,000	$12.07	111,923	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.650 to $65.640. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.660 to $65.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.650 to $64.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.660 to $65.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Halozyme (HALO) CEO Helen Torley report?

Helen Torley reported an exercise-and-sell transaction in Halozyme shares. She exercised options to acquire 40,000 shares at $12.0700 per share, then sold 40,000 common shares in open-market trades at various prices in the mid-$60 range under a Rule 10b5-1 trading plan.

How many Halozyme (HALO) shares did the CEO sell and at what prices?

The CEO sold a total of 40,000 Halozyme common shares. The reported open-market sales occurred at specific per-share prices including $65.3580, $65.7140, $64.0630 and $64.8870, as disclosed in the Form 4 transactions and related weighted-average price footnotes.

What stock options did Helen Torley exercise in this Halozyme (HALO) Form 4?

She exercised stock options covering 40,000 Halozyme shares. The options carried an exercise price of $12.0700 per share and a ten-year term, with expiration in February 2027, reflecting grants originally made on February 22, 2017 and vesting over a four-year period.

How many Halozyme (HALO) shares does the CEO hold after these transactions?

After the reported transactions, Helen Torley directly owned 767,780 Halozyme shares. This post-transaction holding figure is disclosed in the Form 4 as the total number of common shares directly held following the final reported sale entry on April 2, 2026.

Were Helen Torley’s Halozyme (HALO) share sales pre-planned under Rule 10b5-1?

Yes, the filing states the transactions followed a Rule 10b5-1 plan. A footnote explains the options exercised and resulting share sales were made under a written trading plan adopted on March 21, 2025 in accordance with SEC Rule 10b5-1.

What is notable about the options exercised in Helen Torley’s Halozyme (HALO) Form 4?

The exercised options were nearing the end of a ten-year term. The filing notes that the sales involved shares acquired from exercising stock options with a ten-year term expiring in February 2027, originally granted on February 22, 2017 with standard four-year vesting.